Stifel Nicolaus Sticks to Its Buy Rating for Argenx Se (ARGX)


Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Argenx Se (ARGX) today and set a price target of $154.00. The company’s shares closed last Monday at $116.47.

According to TipRanks.com, Archila ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.9% and a 28.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $157.66 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $150.92 and a one-year low of $71.48. Currently, Argenx Se has an average volume of 155.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts